

University of Groningen

The anxious brain

Boshuisen, Marjolein Larissa

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2003

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Boshuisen, M. L. (2003). *The anxious brain: neuroimaging of panic and anxiety*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

References

- Abadie P, Boulenger JP, Benali K, Barre L, Zarifian E, Baron JC (1999): Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. *Eur J Neurosci* 11:1470-1478.
- Abelson JL, Nesse RM (1990): Cholecystokinin-4 and panic [letter; comment]. *Arch Gen Psychiatry* 47:395.
- Abelson JL, Nesse RM (1994): Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses [see comments]. *Biol Psychiatry* 36:73-83.
- Abelson JL, Nesse RM, Vinik AI (1994): Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. *Biol Psychiatry* 36:84-96.
- Adinoff R, Devous MD, Best SM, George MS, Alexander D, Payne K (2001): Limbic responsiveness to procaine in cocaine-addicted subjects. *Am J Psychiatry* 158:390-398.
- Adolphs R, Tranel D, Damasio H, Damasio A (1994): Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala [see comments]. *Nature* 372:669-672.
- Albus M, Zahn TP, Breier A (1992): Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. *Eur Arch Psychiatry Clin Neurosci* 241:337-344.
- American Psychiatric Association Committee on Nomenclature and Statistics (1980): Diagnostic and statistical manual of mental disorders (3rd. ed.) DSM-III . Washington DC: American Psychiatric Press.
- American Psychiatric Association Committee on Nomenclature and Statistics (1987): Diagnostic and Statistical Manual of Mental Disorders (3rd ed., revised) , 3 ed. Washington DC: The Association.
- American Psychiatric Association Committee on Nomenclature and Statistics (1994): Diagnostic and Statistical Manual of Mental Disorders: edition 4 (DSM-IV) . Washington DC: American Psychiatric Association.
- American Psychiatric Association Committee on Nomenclature and Statistics (1998): Practice guideline for the treatment of patients with panic disorder. *Am J Psychiatry* 155:1-34.
- Bakker A, van Balkom AJLM, van Dyck R (2000): Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. *Int Clin Psychopharm* 15 Suppl. 2:S25-S30.
- Battaglia M, Bertella S, Ogliari A, Bellodi L, Smeraldi E (2001): Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. *Arch Gen Psychiatry* 58:114-119.
- Baxter LRJ, Mazziotta JC, Phelps ME, Selin CE, Guze BH, Fairbanks L (1987a): Cerebral glucose metabolic rates in normal human females versus normal males. *Psychiatry Res* 21:237-245.
- Baxter LRJ, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH et al (1988): Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. *Am J Psychiatry* 145:1560-1563.
- Baxter LRJ, Thompson JM, Schwartz JM, Guze BH, Phelps ME, Mazziotta JC et al (1987b): Trazodone treatment response in obsessive-compulsive disorder—correlated with shifts in glucose metabolism in the caudate nuclei. *Psychopathology* 20 Suppl 1:114-122.
- Baxter LJ, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC et al (1992): Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. *Arch Gen Psychiatry* 49:681-689.
- Beard,GM (1881): Symptoms of Neurasthenia. In Beard,GM, editor. *A practical Treatise on Nervous Exhaustion (Neurasthenia), Its Symptoms, Nature, Sequence, Treatment*. New York: Putnam's Sons.
- Beinfeld MC, Palkovits M (1981): Distribution of cholecystokinin in the hypothalamus and the limbic system of the rat. *Neuropeptides* 2:123-129.
- Benedikt M (1870): Ueber "Platzschwindel". *Allgem Wiener Med Zeitung* 15:488-489.

- Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A et al (1995): Functional neuroanatomy of CCK₄-induced anxiety in normal healthy volunteers [see comments]. *Am J Psychiatry* 152:1180-1184.
- Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM (1990): Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. *Arch Gen Psychiatry* 47:840-848.
- Bennett JA, Moioffer M, Stanton SP, Dwight M, Keck PE (1998): A risk-benefit assessment of pharmacological treatments for panic disorder. *Drug Safety* 18:419-430.
- Bertani A, Bellodi L, Bussi R, Caldirola D, Cucchi M, Perna G (2003): The Effect of One-Week Treatment with Venlafaxine on 35% CO₂ Hyperreactivity in Patients with Panic Disorder: An Open Study. *J Clin Psychopharmacol* 23:106-108.
- Bertani A, Caldirola D, Bussi R, Bellodi L, Perna G (2001): The 35% CO₂ hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. *J Clin Psychopharmacol* 21:262-267.
- Birbaumer N, Grodd W, Diedrich O, Klose U, Erb M, Lotze M et al (1998): fMRI reveals amygdala activation to human faces in social phobics. *Neuroreport* 9:1223-1226.
- Bisaga A, Katz JL, Antonini A, Wright CE, Margoueff C, Gorman JM et al (1998): Cerebral glucose metabolism in women with panic disorder. *Am J Psychiatry* 155:1178-1183.
- Boshuisen ML, Slaap BR, Vester-Blokland ED, Den Boer JA (2001): The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. *Int Clin Psychopharmacology* 16:363-368.
- Boshuisen ML, Ter Horst GJ, Paans AMJ, Reinders A-ATS, den Boer JA (2002): rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. *Biol Psychiatry* 52:126-135.
- Bourin M, Malinge M, Guitton B (1995): Provocative agents in panic disorder. *Therapie* 50:301-306.
- Bradwejn J (1993): Neurobiological investigations into the role of cholecystokinin in panic disorder. *J Psychiatry Neurosci* 18:178-188.
- Bradwejn J, de Montigny C (1984): Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. *Nature* 312:363-364.
- Bradwejn J, Koszycki D (1991): Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 15:237-239.
- Bradwejn J, Koszycki D (1994a): Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. *Am J Psychiatry* 151:261-263.
- Bradwejn J, Koszycki D (1994b): The cholecystokinin hypothesis of anxiety and panic disorder. *Ann N Y Acad Sci* 713:273-282.
- Bradwejn J, Koszycki D (2001): Cholecystokinin and panic disorder: past and future clinical research strategies. *Scand J Clin Lab Invest Suppl* :19-27.
- Bradwejn J, Koszycki D, Annable L, Couetoux-du TA, Reines S, Karkanas C (1992a): A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. *Biol Psychiatry* 32:903-912.
- Bradwejn J, Koszycki D, Bourin M (1991a): Dose ranging study of the effects of cholecystokinin in healthy volunteers. *J Psychiatry Neurosci* 16:91-95.
- Bradwejn J, Koszycki D, Couetoux-du TA, Paradis M, Bourin M (1994a): Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. *Psychopharmacology* 114:257-261.
- Bradwejn J, Koszycki D, Couetoux-du TA, van Megen H, den Boer J, Westenberg H (1994b): The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. *Arch Gen Psychiatry* 51:486-493.

- Bradwejn J, Koszycki D, Meterissian G (1990): Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. *Can J Psychiatry* 35:83-85.
- Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992b): Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. *Am J Psychiatry* 149:962-964.
- Bradwejn J, Koszycki D, Shriqui C (1991b): Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. *Arch Gen Psychiatry* 48:603-610.
- Brawman MO, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N et al (1997): Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. *Am J Psychiatry* 154:700-702.
- Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA et al (1997): Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. *Arch Gen Psychiatry* 54:246-254.
- Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW et al (2000): SPECT [¹²³I]-lomazenil measurement of the benzodiazepine receptor in panic disorder. *Biol Psychiatry* 47:96-106.
- Bremner JD, Staib LH, Kaloupek D, Southwick SM, Soufer R, Charney DS (1999): Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: A positron emission tomography study. *Biol Psychiatry* 45:806-816.
- Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME et al (1998): FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. *Psychiatry Res* 84:1-6.
- Bystritsky A, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY (2001): Functional MRI changes during panic anticipation and imagery exposure. *Neuroreport* 12:3953-3957.
- Cahill L, Haier RJ, White NS, Fallon J, Kilpatrick L, Lawrence C et al (2001): Sex-related difference in amygdala activity during emotionally influenced memory storage. *Neurobiology of Learning and Memory* 75:1-9.
- Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR (1992): Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. *Acta Psychiatr Scand* 86:273-282.
- Chen IW, Dorley JM, Ramjit HG, Pitzenberger SM, Lin JH (1992): Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. *Drug Metab Dispos* 20:390-395.
- Cheng DT, Knight DC, Smith CN, Stein EA, Helmstetter FJ (2003): Functional MRI of human amygdala activity during Pavlovian fear conditioning: stimulus processing versus response expression. *Behav Neurosci* 117:3-10.
- Chua P, Krams M, Toni I, Passingham R, Dolan R (1999): A functional anatomy of anticipatory anxiety. *Neuroimage* 9:563-571.
- Clark DM (1993): Cognitive mediation of panic attacks induced by biological challenge tests. *Adv Behav Res Ther* 15:75-84.
- Coplan,JD, Klein,DF (1996): Pharmacological probes in panic disorder. In Westenberg,HGM, den Boer,J, Murphy,DL, editors. *Advances in the neurobiology of anxiety disorders*. Chichester: John Wiley & Sons Ltd, pp 173-196.
- Coupland N, Malizia A, Bailey J, Nutt D (1996): Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment]. *Biol Psychiatry* 39:465-466.
- Cowley DS, Hyde TS, Dager SR, Dunner DL (1987): Lactate infusions: the role of baseline anxiety. *Psychiatry Res* 21:169-179.

- Da Costa JM (1871): On irritable heart: a clinical study of a form of functional cardiac disorder and its consequences. *Am J Med Sci* 71:17-52.
- Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LLB, Parvizi J et al (2000): Subcortical and cortical brain activity during the feeling of self-generated emotions. *Nature Neurosci* 3:1049-1056.
- Davidson RJ (2002): Anxiety and affective style: role of prefrontal cortex and amygdala. *Biol Psychiatry* 51:68-80.
- Davidson RJ, Marshall JR, Tomarken AJ, Henriques JB (2000): While a phobic waits: Regional brain electrical and autonomic activity in social phobics during anticipation of public speaking. *Biol Psychiatry* 47:85-95.
- Davis M (1997): Neurobiology of fear responses: The role of the amygdala. *J Neuropsychiatry Clin Neurosci* 9:382-402.
- Davis M (1998): Are different parts of the extended amygdala involved in fear versus anxiety? *Biol Psychiatry* 44:1239-1247.
- De Bellis MD, Casey BJ, Dahl RE, Birmaher B, Williamson DE, Thomas KM et al (2000): A pilot study of amygdala volumes in pediatric generalized anxiety disorder. *Biol Psychiatry* 48:51-57.
- De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C (1993): Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. *Biol Psychiatry* 33:505-512.
- de Leeuw AS, Den Boer JA, Slaap BR, Westenberg HG (1996): Pentagastrin has panic-inducing properties in obsessive compulsive disorder. *Psychopharmacology* 126:339-344.
- de Montigny C (1989): Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings [see comments]. *Arch Gen Psychiatry* 46:511-517.
- Deakin JF (1991): Depression and 5HT. *Int Clin Psychopharmacol* 6 Suppl 3:23-28.
- Deakin, JF (1999): Making sense of serotonin (5HT) and its role in common psychopathology. In Tansella, M, Thornicroft, G, editors. *Common Mental Disorders in Primary Care*. London: Routledge, pp 17-33.
- Den Boer JA, Bosker FJ, Slaap BR (2000): Serotonergic drugs in the treatment of depressive and anxiety disorders. *Hum Psychopharmacol Clin Exp* 15:315-336.
- Den Boer, JA, Slaap, BR, Ter Horst, GJ, Cremers, TIFH, Bosker, FJ (2002): Therapeutic armamentarium in anxiety disorders. In D'haenen, H, Den Boer, JA, Willner, P, editors. *Biological Psychiatry*. Chichester: John Wiley & Sons, Ltd, pp 1039-1060.
- Den Boer, JA, van Hout W.J.P.J., Nielen, MMA, Ter Horst, GJ (in press 2003): Neuropsychiatrie van paniekstoornis: een integratie van neurobiologische en psychologische modellen. In Eling, P, De Haan, E, Hijman, R, Schmand, B, editors. *Cognitieve neuropsychiatrie*. Amsterdam: Boom.
- Den Boer JA, Westenberg HG, Kamerbeek WD, Verhoeven WM, Kahn RS (1987): Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. *Int Clin Psychopharmacol* 2:21-32.
- den Boer JA, Westenberg HGM, Klompmakers AA, van Lint LE (1989): Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. *Biol Psychiatry* 26:612-622.
- Dodd J, Kelly JS (1981): The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. *Brain Res* 205:337-350.
- Drevets WC, Videen TQ, MacLeod AK, Haller JW, Raichle ME (1992): PET images of blood flow changes during anxiety: correction [letter]. *Science* 256:1696.
- Ebihara M, Ohba H, Hattori E, Yamada K, Yoshikawa T (2003): Transcriptional activities of cholecystokinin promoter haplotypes and their relevance to panic disorder susceptibility. *Am J Med Genet* 118B:32-35.

- Fernandez M, Pissioti A, Frans O, von Knorring L, Fischer H, Fredrikson M (2001): Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study. *Neurosci Lett* 297:101-104.
- Fischer H, Andersson JLR, Furmark T, Fredrikson M (1998): Brain correlates of an unexpected panic attack: a human positron emission tomographic study. *Neurosci Lett* 251:137-140.
- Fischer H, Wik G, Fredrikson M (1996): Functional neuroanatomy of robbery re-experience: affective memories studied with PET. *Neuroreport* 7:2081-2086.
- Flint A, Bradwejn J, Vaccarino F, Gutkowska J, Palmour R, Koszycki D (2002): Aging and panicogenic response to cholecystinin tetrapeptide: an examination of the cholecystinin system. *Neuropsychopharmacol* 27:663-671.
- Fontaine R, Breton G, Dery R, Fontaine S, Elie R (1990): Temporal lobe abnormalities in panic disorder: an MRI study. *Biol Psychiatry* 27:304-310.
- Fredrikson M, Wik G, Annas P, Ericson K, Stone ES (1995): Functional neuroanatomy of visually elicited simple phobic fear: additional data and theoretical analysis. *Psychophysiology* 32:43-48.
- Fredrikson M, Wik G, Greitz T, Eriksson L, Stone ES, Ericson K et al (1993): Regional cerebral blood flow during experimental phobic fear. *Psychophysiology* 30:126-130.
- Freud S (1895a): Obsessions et Phobies. *Gesammelte Werke, Band I* :343-355.
- Freud S (1895b): Ueber die Berechtigung, von der Neurasthenie einen bestimmten Symptomen-komplex als "Angstneurose" abzutrennen. *Gesammelte Werke, Band I* :315-342.
- Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD (1996): Detecting activations in PET and fMRI: levels of inference and power. *Neuroimage* 4:223-235.
- Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ (1995): Statistical parametric maps in functional imaging: a general linear approach. *Hum Brain Mapp* 2:189-210.
- Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissioti A, Langstrom B et al (2002): Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. *Arch Gen Psychiatry* 59:425-433.
- Genovese CR, Lazar NA, Nichols T (2002): Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage* 15:870-878.
- George MS, Ketter TA, Parekh PI, Herscovitch P, Post RM (1996): Gender differences in regional cerebral blood flow during transient self-induced sadness or happiness. *Biol Psychiatry* 40:859-871.
- Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD (2002): Pentagastrin-induced sleep panic attacks: Panic in the absence of elevated baseline arousal. *Biol Psychiatry* 52:1183-1189.
- Glas,G (2003): A conceptual history of anxiety and depression. In Kasper,S, den Boer,JA, Sitsen,JMA, editors. *Handbook of depression and anxiety*. New York: Marcel Dekker Inc, pp 1-47.
- Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OAC et al (2001): Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. *Arch Gen Psychiatry* 58:556-561.
- Goldberg D (1996): A dimensional model for common mental disorders. *Br J Psychiatry Suppl* :44-49.
- Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM et al (1984): Response to hyperventilation in a group of patients with panic disorder. *Am J Psychiatry* 141:857-861.
- Gorman, JM, Fyer, MR, Liebowitz, MR, Klein, DF (1987): Pharmacological provocation of panic attacks. In Meltzer, HY, editor. *Psychopharmacology: A Third Generation of Progress*. New York: Raven Press, pp 980-983.

- Gorman JM, Kent J, Martinez J, Browne S, Coplan J, Papp LA (2001): Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder - Evidence for a central fear mechanism. *Arch Gen Psychiatry* 58:125-131.
- Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000): Neuroanatomical hypothesis of panic disorder, revised. *Am J Psychiatry* 157:493-505.
- Gorman JM, Liebowitz MR, Fyer AJ, Stein J (1989): A neuroanatomical hypothesis for panic disorder. *Am J Psychiatry* 146:148-161.
- Griez E, de Loof C, Pols H, Zandbergen J, Lousberg H (1990): Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. *Psychiatry Res* 31:193-199.
- Gutmacher LB, Murphy DL, Insel TR (1983): Pharmacologic models of anxiety. *Compr Psychiatry* 24:312-326.
- Haefely W (1994): Benzodiazepines, benzodiazepine receptors and endogenous ligands. In Den Boer JA, Sitsen JMA, editors. *Handbook of depression and anxiety. A biological approach*. New York: Marcel Dekker, pp 573-609.
- Hamilton M (1959): The assessment of anxiety states by rating. *Br J Med Psychol* 32:50-55.
- Hamilton M (1967): Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 6:278-296.
- Hamilton SP, Slager SL, Helleby L, Heiman GA, Klein DF, Hodge SE et al (2001): No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. *Mol Psychiatry* 6:59-65.
- Haradahira T, Inoue O, Kobayashi K, Suzuki K (1998): Synthesis and evaluation of ¹¹C-labeled nonpeptide antagonists for cholecystokinin receptors: [¹¹C]L-365,260 and [¹¹C]L-365,346. *Nucl Med Biol* 25:203-208.
- Hariri AR, Mattay VS, Tessitore A, Fera F, Weinberger DR (2003): Neocortical modulation of the amygdala response to fearful stimuli. *Biol Psychiatry* 53:494-501.
- Harro J, Pold M, Vasar E (1990): Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. *Naunyn Schmiedebergs Arch Pharmacol* 341:62-67.
- Harro J, Vasar E, Bradwejn J (1993): CCK in animal and human research on anxiety. *Trends Pharmacol Sci* 14:244-249.
- Hattori E, Ebihara M, Yamada K, Ohba H, Shibuya H, Yoshikawa T (2001a): Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. *Mol Psychiatry* 6:465-470.
- Hattori E, Yamada K, Toyota T, Yoshitsugu K, Toru M, Shibuya H et al (2001b): Association studies of the CT repeat polymorphism in the 5' upstream region of the cholecystokinin B receptor gene with panic disorder and schizophrenia in Japanese subjects. *Am J Med Genet* 105:779-782.
- Hirschfeld RMA (2000): Sertraline in the treatment of anxiety disorders. *Depression and Anxiety* 11:139-157.
- Ise K, Akiyoshi J, Horinouchi Y, Tsutsumi T, Isogawa K, Nagayama H (2003): Association between the CCK-A receptor gene and panic disorder. *Am J Med Genet* 118B:29-31.
- Ivy AC, Oldberg E (1928): Hormone mechanism for gallbladder contraction and evacuation. *Am J Physiol* 86:599-613.
- Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J (1999): Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: A comparison of two time points. *Biol Psychiatry* 45:872-882.

- Johanson A, Gustafson L, Passant U, Risberg J, Smith G, Warkentin S et al (1998): Brain function in spider phobia. *Psychiatry Res Neuroimaging* 84:101-111.
- Kalin NH, Shelton SE, Davidson RJ, Kelley AE (2001): The primate amygdala mediates acute fear but not the behavioral and physiological components of anxious temperament. *J Neurosci* 21:2067-2074.
- Karknias CD, Block GA, Reines S, Bradwejn J (1989): Neurobiology of panic disorder [letter]. *Am J Psychiatry* 146:1357.
- Kaschka W, Feistel H, Ebert D (1995): Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. *J Psychiatr Res* 29:427-434.
- Kastrop A, Li TQ, Glover GH, Kruger G, Moseley ME (1999): Gender differences in cerebral blood flow and oxygenation response during focal physiologic neural activity. *J Cereb Blood Flow Metab* 19:1066-1071.
- Katschnig H (1999): Anxiety neurosis, panic disorder or what? In Nutt, DJ, Ballenger, JC, Lepine, J-P, editors. *Panic Disorder: Clinical Diagnosis, Management and Mechanisms*. London: Martin Dunitz Ltd, pp 1-8.
- Katzman MA, Duffin J, Shlik J, Bradwejn J (2002): The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers. *Neuropsychopharmacol* 26:824-831.
- Kellner M, Yassouridis A, Hua Y, Wendrich M, Naber D, Wiedemann K (2002): Trait dissociation affects the behavioral response to cholecystokinin tetrapeptide in healthy man. *Psychiatry Res* 111:93-96.
- Kendell RE (1975): The concept of disease and its implications for psychiatry. *Br J Psychiatry* 127:305-315.
- Kent JM, Papp LA, Martinez JM, Browne ST, Coplan JD, Klein DF et al (2001): Specificity of panic response to CO₂ inhalation in panic disorder: A comparison with major depression and premenstrual dysphoric disorder. *Am J Psychiatry* 158:58-67.
- Klein, DF (1981): Anxiety reconceptualized. In Klein, DF, Rabkin, J, editors. *Anxiety: New Research and Changing Concepts*. New York: Raven Press, pp 235-263.
- Klein DF, Klein HM (1989): The utility of the panic disorder concept. *Eur Arch Psychiatry Neurol Sci* 238:268-279.
- Knott VJ, Mahoney C, Gunnarsson T, Bradwejn J, Shlik J (2002): Acute cholecystokinin effects on event-related potentials in healthy volunteers. *Hum Psychopharmacol* 17:285-291.
- Koszycki D, Bradwejn J, Bourin M (1991): Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. *Eur Neuropsychopharmacol* 1:137-141.
- Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A et al (1995): A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. *Biol Psychiatry* 37:462-466.
- Kronenberg G, Schredl M, Fiedler K, Heuser I (2001): In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep. *Depress Anxiety* 14:141-144.
- Kuikka JT, Pitkanen A, Lepola U, Partanen K, Vainio P, Bergstrom KA et al (1995): Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. *Nucl Med Commun* 16:273-280.
- Layton ME, Friedman SD, Dager SR (2001): Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. *Depress Anxiety* 14:251-254.
- Le Melleo J, Jhangri GS, Lott P, Tait GR, McManus K, Geddes M et al (2001a): Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder. *Psychiatry Res* 101:237-242.
- Le Melleo JM, Arthur H, Dalton J, Woo C, Lipton N, Bellavance F et al (2001b): The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. *J Psychosom Res*

- 51:513-520.
- LeDoux J (1996): Emotional networks and motor control: a fearful view. *Prog Brain Res* 107:437-446.
 - LeDoux J (1998): Fear and the brain: where have we been, and where are we going? [see comments]. *Biol Psychiatry* 44:1229-1238.
 - LeDoux JE (1994): Emotion, memory and the brain. *Sci Am* 270:32-39.
 - LeDoux,JE (2002): *Synaptic self: how our brains become who we are* . New York: Viking.
 - LeDoux JE, Cicchetti P, Xagoraris A, Romanski LM (1990): The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning. *J Neurosci* 10:1062-1069.
 - LeDoux JE, Iwata J, Cicchetti P, Reis DJ (1988): Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. *J Neurosci* 8:2517-2529.
 - Lee MA, Flegel P, Greden JF, Cameron OG (1988): Anxiogenic effects of caffeine on panic and depressed patients. *Am J Psychiatry* 145:632-635.
 - Lepola U, Nousiainen U, Puranen M, Riekkinen P, Rimon R (1990): EEG and CT findings in patients with panic disorder. *Biol Psychiatry* 28:721-727.
 - Levin P, Lazrove S, Van der Linden KB (1999): What psychological testing and neuroimaging tell us about the treatment of Posttraumatic Stress Disorder by Eye Movement Desensitization and Reprocessing. *J Anxiety Disord* 13:159-172.
 - Liberzon I, Taylor SF, Amdur R, Jung TD, Chamberlain KR, Minoshima S et al (1999): Brain activation in PTSD in response to trauma-related stimuli. *Biol Psychiatry* 45:817-826.
 - Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G et al (1985): Lactate provocation of panic attacks. II. Biochemical and physiological findings. *Arch Gen Psychiatry* 42:709-719.
 - Londborg PD, Wolkow RM, Smith WT, Duboff E, England D, Ferguson JM et al (1998): Sertraline in the treatment of panic disorder - A multi-site, double-blind, placebo-controlled, fixed-dose investigation. *Br J Psychiatry* 173:54-60.
 - Maclean PD (1949): Psychosomatic disease and the "visceral brain"; recent developments bearing on the Papez theory of emotion. *Psychosom Med* 11:338-353.
 - Maddock RJ (1999): The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. *Trends Neurosci* 22:310-316.
 - Malizia AL (1999): What do brain imaging studies tell us about anxiety disorders? *J Psychopharmacol* 13:372-378.
 - Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ (1998): Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. *Arch Gen Psychiatry* 55:715-720.
 - Margraf J, Ehlers A, Roth WT (1986): Sodium lactate infusions and panic attacks: a review and critique. *Psychosom Med* 48:23-51.
 - Massana G, Serra-Grabulosa JM, Salgado-Pineda P, Gasto C, Junque C, Massana J et al (2003): Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. *Am J Psychiatry* 160:566-568.
 - Massana G, Gasto C, Junque C, Mercader J, Gomez B, Massana J et al (2002): Reduced levels of creatine in the right medial temporal lobe region of panic disorder patients detected with (1)h magnetic resonance spectroscopy. *Neuroimage* 16:836.
 - Massana J, Lopez-Risueno JA, Masana G, Marcos T, Gonzalez L, Otero A (2001): Subtyping of panic disorder patients with bradycardia. *Eur Psychiatry* 16:109-114.
 - Mataix-Cols D, Cullen S, Lange K, Zelaya F, Andrew C, Amaro E et al (2003): Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers. *Biol Psychiatry* 53:482-493.

- Mathew RJ, Wilson WH (1990a): Anxiety and cerebral blood flow. *Am J Psychiatry* 147:838-849.
- Mathew RJ, Wilson WH (1990b): Behavioral and cerebrovascular effects of caffeine in patients with anxiety disorders. *Acta Psychiatr Scand* 82:17-22.
- McCann UD, Slate SO, Geraci M, RoscowTerrill D, Uhde TW (1997): A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. *Neuropsychopharmacol* 16:229-237.
- McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ (1994): Functional anatomy of obsessive-compulsive phenomena. *Br J Psychiatry* 164:459-468.
- McManus K, Tait GR, Bellavance F, Le Melleo JM (2001): Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin. *J Affect Disord* 66:273-279.
- Meyer JH, Swinson R, Kennedy SH, Houle S, Brown GM (2000): Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. *Psychiatry Res Neuroim* 98:133-143.
- Morel BA (1866): *Du Delire Emotif*. *Archives generales de medecine* 1:385-402.
- Morris JS, Scott SK, Dolan RJ (1999): Saying it with feeling: neural responses to emotional vocalizations. *Neuropsychologia* 37:1155-1163.

- Nashold BSJ, Wilson WP, Slaughter DG (1969): Sensations evoked by stimulation in the mid-brain of man. *J Neurosurg* 30:14-24.
- Nitschke JB, Heller W, Palmieri PA, Miller GA (1999): Contrasting patterns of brain activity in anxious apprehension and anxious arousal. *Psychophysiology* 36:628-637.
- Nordahl TE, Semple WE, Gross M, Mellman TA, Stein MB, Goyer P et al (1990): Cerebral glucose metabolic differences in patients with panic disorder. *Neuropsychopharmacol* 3:261-272.
- Nordahl TE, Stein MB, Benkelfat C, Semple WE, Andreason P, Zametkin A et al (1998): Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. *Biol Psychiatry* 44:998-1006.
- Nutt, DJ, Ballenger, JC, Lepine, J-P (1999): *Panic Disorder: Clinical Diagnosis, Management and Mechanisms*. London: Martin Dunitz Ltd.
- Nutt DJ, Glue P, Lawson C, Wilson S (1990): Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder [see comments]. *Arch Gen Psychiatry* 47:917-925.

- O'Rourke D, Fahy TJ, Prescott P (1996): The Galway Study of Panic Disorder. IV. Temporal stability of diagnosis by present state examination test-retest. *Br J Psychiatry* 169:98-100.
- Ochsner KN, Bunge SA, Gross JJ, Gabrieli JD (2002): Rethinking feelings: an fMRI study of the cognitive regulation of emotion. *J Cogn Neurosci* 14:1215-1229.
- Olsson M, Ho HP, Annerbrink K, Thylefors J, Eriksson E (2002): Respiratory responses to intravenous infusion of sodium lactate in male and female Wistar rats. *Neuropsychopharmacol* 27:85-91.
- Ontiveros A, Fontaine R, Breton G, Elie R, Fontaine S, Dery R (1989): Correlation of severity of panic disorder and neuroanatomical changes on magnetic resonance imaging. *J Neuropsychiatry Clin Neurosci* 1:404-408.
- Otte C, Kellner M, Arlt J, Jahn H, Holsboer F, Wiedemann K (2002): Prolactin but not ACTH increases during sodium lactate-induced panic attacks. *Psychiatry Res* 109:201-205.

- Papez JW (1937): A proposed mechanism of emotion. *Arch Neurol Psychiatry* 38:725-743.
- Paquette V, Levesque J, Mensour B, Leroux JM, Beaudoin G, Bourgouin P et al (2003): "Change the mind and you change the brain": effects of cognitive-behavioral therapy on the neural correlates of spider phobia. *Neuroimage* 18:401-409.

- Paulson OB (2002): Blood-brain barrier, brain metabolism and cerebral blood flow. *Eur Neuropsychopharmacol* 12:495-501.
- Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S et al (1995): [¹⁸F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. *Br J Psychiatry* 166:244-250.
- Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L (2002): Antipanic drug modulation of 35% CO₂ hyperreactivity and short-term treatment outcome. *J Clin Psychopharmacol* 22:300-308.
- Pissiota A, Frans O, Fernandez M, von Knorring L, Fischer H, Fredrikson M (2002): Neurofunctional correlates of posttraumatic stress disorder: a PET symptom provocation study. *Eur Arch Psychiatry Clin Neurosci* 252:68-75.
- Pitts FN, McClure JN (1967): Lactate metabolism in anxiety neurosis. *N Engl J Med* 277:1329-1336.
- Pohl RB, Wolkow RM, Clary CM (1998): Sertraline in the treatment of panic disorder: A double-blind multicenter trial. *Am J Psychiatry* 155:1189-1195.
- Pollack MH, Marzol PC (2000): Panic: course, complications and treatment of panic disorder. *J Psychopharmacology* 14:S25-S30.
- Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998): Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. *Arch Gen Psychiatry* 55:1010-1016.
- Pols H, Verburg K, Griez E (1994): Carbon-Dioxide-Induced Panic. *Am J Psychiatry* 151:292-293.
- Ponto LLB, Kathol RG, Kettelkamp R, Watkins GL, Richmond JCW, Clark J et al (2002): Global cerebral blood flow after CO₂ inhalation in normal subjects and patients with panic disorder determined with [¹⁵O]water and PET. *J Anxiety Disord* 16:247-258.
- Radu D, Ahlin A, Svanborg P, Lindfors N (2002): Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. *Psychopharmacology* 161:396-403.
- Radu D, Ahlin A, Svanborg P, Lindfors N (2003): Pentagastrin test for anxiety—psychophysiology and personality. *Psychopharmacology* 166:139-145.
- Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2001): Sertraline treatment of panic disorder: results of a long-term study. *Acta Psychiatr Scand* 104:289-298.
- Rassovsky Y, Kushner MG (2003): Carbon dioxide in the study of panic disorder: issues of definition, methodology, and outcome. *J Anxiety Disord* 17:1-32.
- Rauch SL, Savage CR, Alpert NM, Fischman AJ, Jenike MA (1997): The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. *Biol Psychiatry* 42:446-452.
- Rauch SL, Savage CR, Alpert NM, Miguel EC, Baer L, Breiter HC et al (1995): A positron emission tomographic study of simple phobic symptom provocation. *Arch Gen Psychiatry* 52:20-28.
- Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR et al (1996): A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. *Arch Gen Psychiatry* 53:380-387.
- Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA (2002): Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. *Neuropsychopharmacol* 27:782-791.
- Rehfeld JF (2000): Cholecystokinin and panic disorder - three unsettled questions. *Reg Peptides* 93:79-83.
- Reiman EM (1997): The application of positron emission tomography to the study of normal and pathologic emotions. *J Clin Psychiatry* 58 Suppl 16:4-12.

- Reiman EM, Fusselman MJ, Fox PT, Raichle ME (1989a): Neuroanatomical correlates of anticipatory anxiety [published erratum appears in *Science* 1992 Jun 19;256(5064):1696]. *Science* 243:1071-1074.
- Reiman EM, Lane RD, Ahern GL, Schwartz GE, Davidson RJ, Friston KJ et al (1997): Neuroanatomical correlates of externally and internally generated human emotion. *Am J Psychiatry* 154:918-925.
- Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E (1984): A focal brain abnormality in panic disorder, a severe form of anxiety. *Nature* 310:683-685.
- Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P et al (1986): The application of positron emission tomography to the study of panic disorder. *Am J Psychiatry* 143:469-477.
- Reiman EM, Raichle ME, Robins E, Mintun MA, Fusselman MJ, Fox PT et al (1989b): Neuroanatomical correlates of a lactate-induced anxiety attack. *Arch Gen Psychiatry* 46:493-500.
- Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al (2003): Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. *J Neurosci* 23:349-357.
- Sanchez-Fernandez C, Gonzalez C, Mercer LD, Beart PM, Ruiz-Gayo M, Fernandez-Alfonso MS (2003): Cholecystokinin Induces Cerebral Vasodilatation via Presynaptic CCK2 Receptors: New Implications for the Pathophysiology of Panic. *J Cereb Blood Flow Metab* 23:364-370.
- Saxena S, Brody AL, Schwartz JM, Baxter LR (1998): Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. *Br J Psychiatry Suppl* :26-37.
- Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N et al (2002): Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. *Arch Gen Psychiatry* 59:250-261.
- Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O (1994): Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. *Eur Arch Psychiatry Clin Neurosci* 244:49-51.
- Schwartz JM, Stoessel PW, Baxter LRJ, Martin KM, Phelps ME (1996): Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. *Arch Gen Psychiatry* 53:109-113.
- Sheehan DV (1999): Current concepts in the treatment of panic disorder. *J Clin Psychiatry* 60 Suppl. 18:16-21.
- Shin LM, McNally RJ, Kosslyn SM, Thompson WL, Rauch SL, Alpert NM et al (1999): Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD: A PET investigation. *Am J Psychiatry* 156:575-584.
- Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997): Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. *J Psychiatry Neurosci* 22:332-340.
- Shlik J, Zhou YP, Koszycki D, Vaccarino FJ, Bradwejn J (1999): Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. *J Psychopharmacol* 13:385-390.
- Sinton CM (1988): Cholecystokinin and cholecystokinin antagonists enhance postsynaptic excitability in the dentate gyrus. *Peptides* 9:1049-1053.
- Spitzer RL, Endicott J, Robins E (1978): Research diagnostic criteria: rationale and reliability. *Arch Gen Psychiatry* 35:773-782.
- Stewart RS, Devous-MD S, Rush AJ, Lane L, Bonte FJ (1988): Cerebral blood flow changes during sodium-lactate-induced panic attacks. *Am J Psychiatry* 145:442-449.
- Strohle A, Kellner M, Holsboer F, Wiedemann K (1999): Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensi-

- tivity in panic disorder. *Biol Psychiatry* 45:321-326.
- Strohle A, Kellner M, Holsboer F, Wiedemann K (2001): Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. *Am J Psychiatry* 158:1514-1516.
 - Strohle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G et al (2003): Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. *Arch Gen Psychiatry* 60:161-168.
 - Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL et al (1992): Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. *Arch Gen Psychiatry* 49:690-694.
 - Talairach, J, Tournoux, P (1988): *Co-Planar Stereotaxic Atlas of the Human Brain*. New York: Thieme.
 - Tarlo SM, Poonai N, Binkley K, Antony MM, Swinson RP (2002): Responses to panic induction procedures in subjects with multiple chemical sensitivity/idiopathic environmental intolerance: understanding the relationship with panic disorder. *Environ Health Perspect* 110 Suppl 4:669-671.
 - Tillfors M, Furmark T, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B et al (2001): Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. *Am J Psychiatry* 158:1220-1226.
 - Uhde TW, Kellner CH (1987): Cerebral ventricular size in panic disorder. *J Affect Disord* 12:175-178.
 - Valenca AM, Nardi AE, Nascimento I, Zin WA, Lopes FL, Mezzasalma MA et al (2002a): Early carbon dioxide challenge test may predict clinical response in panic disorder. *Psychiatry Res* 112:269-272.
 - Valenca AM, Nardi AE, Nascimento I, Zin WA, Versiani M (2002b): Respiratory panic disorder subtype and sensitivity to the carbon dioxide challenge test. *Braz J Med Biol Res* 35:783-788.
 - Valenca AM, Nardi AE, Nascimento I, Zin WA, Versiani M (2002c): Carbon dioxide test as an additional clinical measure of treatment response in panic disorder. *Arq Neuropsiquiatr* 60:358-361.
 - van Balkom AJLM, Bakker A, Spinhoven P, Blaauw BMJW, Smeenk S, Ruesink B (1997): A meta-analysis of the treatment of panic disorder with or without agoraphobia: A comparison of psychopharmacological, cognitive-behavioral, and combination treatments. *J Nerv Ment Dis* 185:510-516.
 - van den Hout MA, Griez E (1984): Panic symptoms after inhalation of carbon dioxide. *Br J Psychiatry* 144:503-507.
 - Van der Linden LG, Van Heerden B, Warwick J, Wessels C, Van Kradenburg J, Zungu DN et al (2000): Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. *Progress in Neuro Psychopharmacol Biol Psychiatry* 24:419-438.
 - van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS (1996a): Cholecystokinin in anxiety. *Eur Neuropsychopharmacol* 6:263-280.
 - van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS (1996b): The panic-inducing properties of the cholecystokinin tetrapeptide CCK₄ in patients with panic disorder. *Eur Neuropsychopharmacol* 6:187-194.
 - van Megen HJ, Westenberg HG, Den Boer JA, Slaap B, Scheepmakers A (1997a): Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. *Psychopharmacology* 129:357-364.

- van Megen HJ, Westenberg HG, Den Boer JA, Slaap B, van Es RF, Pande AC (1997b): The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. *Psychopharmacology* 129:243-248.
- Van Megen HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M (1994): Pentagastrin Induced Panic Attacks - Enhanced Sensitivity in Panic Disorder Patients. *Psychopharmacology* 114:449-455.
- van Praag HM (1989): Moving ahead yet falling behind. A critical appraisal of some trends in contemporary depression research. *Neuropsychobiol* 22:181-193.
- van Praag HM (2000): Nosologomania: a disorder of psychiatry. *World J Biol Psychiatry* 1:151-158.
- van Praag HM, Asnis GM, Kahn RS, Brown SL, Korn M, Friedman JM et al (1990): Nosological tunnel vision in biological psychiatry. A plea for a functional psychopathology. *Ann N Y Acad Sci* 600:501-510.
- van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A et al (1987): Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. *J Affect Disord* 13:1-8.
- van Vliet IM, Den Boer JA, Westenberg HG, Slaap BR (1996): A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. *J Clin Psychopharmacol* 16:299-306.
- Vythilingam M, Anderson ER, Goddard A, Woods SW, Staib LH, Charney DS et al (2000): Temporal lobe volume in panic disorder - a quantitative magnetic resonance imaging study. *Psychiatry Res Neuroim* 99:75-82.
- Westenberg, HG, Den Boer, JA, Murphy, DL (1996): *Advances in the neurobiology of anxiety disorders*. Chichester: John Wiley & Sons Ltd.
- Westphal C (1872): Die Agoraphobie. *Archiv fur Psychiatrie und Nervenkrankheiten* :138-161.
- Wiedemann K, Jahn H, Yassouridis A, Kellner M (2001): Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. *Arch Gen Psychiatry* 58:371-377.
- Wik G, Fredrikson M, Ericson K, Eriksson L, Stone ES, Greitz T (1993): A functional cerebral response to frightening visual stimulation. *Psychiatry Res* 50:15-24.
- Windmann S (1998): Panic disorder from a monistic perspective: integrating neurobiological and psychological approaches. *J Anxiety Disord* 12:485-507.
- Woods SW, Koster K, Krystal JK, Smith EO, Zubal IG, Hoffer PB et al (1988): Yohimbine alters regional cerebral blood flow in panic disorder [letter]. *Lancet* 2:678.
- Worsley KJ, Marret S, Neelin P, Vandal AC, Friston KJ, Evans AC (1996): A unified statistical approach for determining significant signals in images of cerebral activation. *Hum Brain Mapp* 4:58-73.
- Yamada K, Hattori E, Shimizu M, Sugaya A, Shibuya H, Yoshikawa T (2001): Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. *J Neural Transm* 108:837-848.
- Yeragani VK, Rainey-JM J, Pohl R, Balon R, Berchou R, Jolly S et al (1988): Preinfusion anxiety and laboratory-induced panic attacks in panic disorder patients. *J Clin Psychiatry* 49:302-306.
- Yeragani VK, Rao R, Jayaraman A, Pohl R, Balon R, Glitz D (2002): Heart rate time series: decreased chaos after intravenous lactate and increased non-linearity after isoproterenol in normal subjects. *Psychiatry Res* 109:81-92.
- Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N et al (2001): Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. *Neuropsychopharmacol* 25:699-703.